Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064634 | 1.00 | LCK (0.46) | LCKCA1CA2PI4KBBRAF | |
| SCHEMBL21839496 | 0.84 | LCK (0.43) | LCKCA1CA2PI4KBBRAF | |
| SCHEMBL31278527 | 0.82 | LCK (0.42) | LCKCA1CA2PI4KBBRAF | |
| SCHEMBL21901580 | 0.82 | LCK (0.45) | LCKCA1CA2PI4KBBRAF | |
| SCHEMBL21901456 | 0.81 | LCK (0.41) | LCKCA1CA2PI4KBBRAF | |
| SCHEMBL28902818 | 0.81 | LCK (0.47) | LCK | |
| SCHEMBL30231217 | 0.81 | LCK (0.47) | LCK | |
| SCHEMBL21839452 | 0.79 | LCK (0.40) | LCKCA1CA2PI4KBBRAF | |
| SCHEMBL21839531 | 0.79 | NPC1 (0.39) | — | |
| SCHEMBL27209852 | 0.79 | CA1 (0.41) | LCKCA1CA2PI4KBBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114195788-B | Tetracyclic compounds and application thereof | 苏州闻天医药科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| CN-112805281-B | KRAS G12C inhibitors | 伊莱利利公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114195788-A | Tetracyclic compound and application thereof | 苏州闻天医药科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-112805281-A | KRAS G12C inhibitors | 伊莱利利公司 | 2021-05-14 | — | — | CN | disclosed |
| US-10968214-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2020081282-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968214-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | LCK 2013/4885CA1 3137/4885CA2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.